Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Edyta, Szałek"'
Autor:
Konrad Lewandowski, Agnieszka Karbownik, Andrzej Czyrski, Hanna Urjasz, Joanna Stanisławiak-Rudowicz, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Acta Poloniae Pharmaceutica, Vol 81, Iss 2, Pp 263-278 (2024)
Olaparib, an oral poly-ADP ribose polymerase (PARP) inhibitor, is a relatively new anticancer drug. It is essential to find TDM-guided dosage for better safety and tolerability of patients. However, first, it is important to develop a suitable analyt
Externí odkaz:
https://doaj.org/article/d88f74306b6e406baae09e6342e10085
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionDepressive spectrum disorders are common and can hinder breastfeeding success. While medications typically pose minimal risk, the concerns persist. This is the first study that investigates the prevalence and characteristics of drug-relat
Externí odkaz:
https://doaj.org/article/d94d50cac166451cbcb7b1e35f7675ce
Autor:
Danuta Szkutnik-Fiedler, Filip Kwiatkowski, Monika Chomej, Dorota Kołodziej, Michał Michalak, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Acta Poloniae Pharmaceutica, Vol 80, Iss 2, Pp 277-287 (2023)
Most hospitalized patients with COVID-19 require complex pharmacotherapy due to underlying diseases, and polypharmacy may significantly increase the risk of drug-drug interactions (DDIs) and, in consequence, trigger adverse effects. The aim of this s
Externí odkaz:
https://doaj.org/article/2824e5cbbb024d909c0d9315f543c220
Publikováno v:
Acta Poloniae Pharmaceutica - Drug Research. 79:777-784
The prognosis for patients with acute myeloid leukaemia (AML) varies depending on genetic factors. The presence of mutations in the fms-like tyrosine kinase 3 (FLT3) gene is found in approximately 30% of AML patients. Midostaurin, a first-generation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::580341859cca7624935671f54bfeb848
https://doi.org/10.32383/appdr/159470
https://doi.org/10.32383/appdr/159470
Autor:
Agnieszka Karbownik, Miłosz Miedziaszczyk, Tomasz Grabowski, Joanna Stanisławiak-Rudowicz, Radosław Jaźwiec, Anna Wolc, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 130, Iss , Pp 110530- (2020)
Sorafenib (SR) is one of the most potent UGT (1A1, 1A9) inhibitors (in in vitro tests). The inhibition of UGT1A1 may cause hyperbilirubinaemia, whereas the inhibition of UGT1A9 and 1A1 may result in drug-drug interactions (DDIs). Tapentadol (TAP) is
Externí odkaz:
https://doaj.org/article/73131a06694d4f599a4e1160a129e30e
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2111 (2021)
Bariatric surgery, which is an effective treatment for obesity, and gastrectomy, which is the primary treatment method for gastric cancer, alter the anatomy and physiology of the digestive system. Weight loss and changes in the gastrointestinal tract
Externí odkaz:
https://doaj.org/article/0dc9f459060846ae9b6aee24c029fa83
Autor:
Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Tomasz Grabowski, Anna Wolc, Joanna Stanisławiak-Rudowicz, Radosław Jaźwiec, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2172 (2021)
A combination of the tyrosine kinase inhibitor—sorafenib—and the opioid analgesic—morphine—can be found in the treatment of cancer patients. Since both are substrates of P-glycoprotein (P-gp), and sorafenib is also an inhibitor of P-gp, their
Externí odkaz:
https://doaj.org/article/eab7ca12e6b04047a2d2383652c3f609
Autor:
Edyta Szałek, Arkadiusz Spychala, Patrycja Kozanecka, Hanna Urjasz, Tomasz Grabowski, Anna Wolc, Elżbieta Długosz, Witold Kycler, Edmund Grześkowiak, Agnieszka Karbownik
Publikováno v:
Acta Poloniae Pharmaceutica - Drug Research. 79:401-407
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90a8c72d8a19deec855bb83855970349
https://doi.org/10.32383/appdr/152216
https://doi.org/10.32383/appdr/152216
Autor:
Dorota Kołodziej, Danuta Szkutnik-Fiedler, Hanna Urjasz, Tomasz Grabowski, Ryszard Bosacki, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Acta Poloniae Pharmaceutica - Drug Research. 78:755-759
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6783bcfc2067c8b85ecc72b85a1e7169
https://doi.org/10.32383/appdr/145934
https://doi.org/10.32383/appdr/145934
Autor:
Agnieszka Karbownik, Danuta Szkutnik-Fiedler, Andrzej Czyrski, Natalia Kostewicz, Paulina Kaczmarska, Małgorzata Bekier, Joanna Stanisławiak-Rudowicz, Marta Karaźniewicz-Łada, Anna Wolc, Franciszek Główka, Edmund Grześkowiak, Edyta Szałek
Publikováno v:
Pharmaceutics, Vol 12, Iss 7, p 600 (2020)
The tyrosine kinase inhibitor sorafenib is the first-line treatment for patients with hepatocellular carcinoma (HCC), in which hyperlipidemia and type 2 diabetes mellitus (T2DM) may often coexist. Protein transporters like organic cation (OCT) and mu
Externí odkaz:
https://doaj.org/article/d7cbe8cda674484da883f39507102113